賴秀穗2006-07-262018-07-092006-07-262018-07-092001http://ntur.lib.ntu.edu.tw//handle/246246/28696本計畫繼續進行已構築完成的 PR-PRRS-ORF3 及PR- PRRS-ORF5(假性狂犬病-豬 生殖及呼吸道症候群-ORF3 及ORF5)複合病毒的豬 隻免疫效力試驗。本實驗共用27 頭5 週齡無PR 及 PRRS 抗體的仔豬，分成6 組，前3 組每組6 頭分 別注射PR-PRRS-ORF3 、PR-PRRS-ORF5 及 PR-PRRS-ORF3 +PR- PRRS-ORF5 各2ml 的活複合 病毒(病毒力價105 TCID50)，其餘3 組每組有3 頭 分別注射一劑量商用PR 及PRRS 活毒疫苗，另外 一組3 頭做為不打疫苗的對照組。所有試驗豬隻在 疫苗施打後4 週，以PRRS-F1 強毒株(105.5TCID50) 以鼻腔接種方式攻擊後，每日記錄體溫變化及觀察 臨床症狀。在打疫苗前及後2、4 週，強毒攻毒前 及攻毒後2、4 週各採取血液供PRRS 及PR 的中和 抗體測定。試驗結果發現；所有試驗豬在施打複合 病毒或商用疫苗後，無任何不正常臨床症狀，而在 以PRRS 強毒攻毒後PR-PRRS-ORF5 組及 PR-PRRS-ORF3+ PR-PRRS-ORF5 的試驗豬12 頭均 無任何不正常臨床反應，PR-PRRS-ORF3 在攻毒後 第5 天6 頭中僅有2 頭的體溫上升到攝氏 40.2-40.5，商用疫苗PRRS 及PR 注射組，每組3 頭中在攻毒後第6 天各有一頭體溫分別在攝氏 40.1-40.2，而對照組3 頭中有2 頭體溫上升到攝氏 40.3-40.5。PR 試驗組3 頭在攻毒後第8 天有一頭斃 死，經解剖觀察斃死原因應與PRRS 的攻毒無關。 在抗體測定方面，PR 及PRRS 抗體係以血清中和 抗體方法來測定，在施打疫苗前各試驗組豬隻的血 清中和抗體力價均小於2，在施打疫苗後2 週，不 論是複合病毒試驗組或商用疫苗PR 及PRRS 及對 照組所測的中和抗體力價均在2 倍以下。但在施打 後4 週， 強毒攻毒前的PR-PRRS-ORF5 、 PR-PRRS-ORF3+ PR-PRRS-ORF5 及PRRS 組的試 驗前者6 頭有2 頭的抗體均為2 倍，而PRRS 組3 頭有2 頭的抗體出現2 倍，另一頭則小於2 倍。其 餘豬隻的PRRS 抗體均小於2 倍。但在強毒攻毒後 2 週的PRRS 的抗體， 在PR-PRRS-ORF5 、 PR-PRRS-ORF3+ PR-PRRS-ORF5 及PRRS 組的 PRRS 病毒血清中和抗體力價則有顯著的上升，這 三組的試驗豬均可檢測到PRRS 抗體，其力價介於 2 至8 倍間，其他組的試驗豬雖在攻毒後2 週亦無 法檢測到PRRS 的中和抗體。至於PR 的病毒血清 中和抗體在施打疫苗後2 週，各組的試驗豬均檢測 不到PR 的中和抗體， 但在免疫4 週後， PR-PRRS-ORF3 、PR-PRRS-ORF5 及PR-PRRS -ORF3+ PR-PRRS-ORF5 三組每組6 頭中各有2 頭 ¯檢測到2 倍的抗體。而PR 商用疫苗免疫組3 頭 中均可檢測到2-4 倍的抗體，PRRS 注射及對照組 的豬隻則無PR 的抗體，在PRRS 強毒攻毒後的PR 抗體並無顯著改變。Constructed chimeric viruses, PR-PRRS-ORF3, PR-PRRS-ORF5, PR-PRRS-ORF3 + PR-PRRS- ORF 5and commercial PR (pseudorabies) and PRRS (porcine reproductive and respiratory syndrome) vaccines were used to vaccinate piglets to test their immunogenicity against PRRS virus. Totally 27 piglets at 5 weeks of age without PR and PRRS antibody were divided into 6 groups; The first three groups, 6 for each were inoculated with PR-PRRS -ORF3, PR-PRRS-ORF5 and PR-PRRS-ORF3 + PR-PRRS-ORF5 chimeric viruses (105 TCID50 /ml) respectively. The rest three groups, 3 for each were inoculated with commercial PR and PRRS and PBS respectively, served as positive and negative control group. All piglets were challenged intra nasally with virulent PRRS-F1 virus (105.5TCID50/ml) at 4 weeks after vaccination. Clinical manifestations and rectal temperature were daily recorded. Blood samples were collected before and 2, 4 weeks after vaccination, before and 2, and 4 weeks after challenge. Clinically all experimental pigs did not show any abnormal signs after vaccination with either constructed chimeric virus or commercial PR and PRRS vaccines. In temperature response, 2 out of 6 of PR-PRRS-ORF3 vaccinated group showed rise in temperature 40.2-40.5 0C at 5 days after challenge. Commercial PR and PRRS vaccines vaccinated group, 1 for each group showed rise in temperature 40.1-40.2 0C at the day 6 after challenge. In negative control group, 2 of 3 had temperature 40.3-40.5 0C. Sero- logically, all sera collected at pre-vaccinated and 2 weeks after vaccination showed antibody titer less than 2X against PR and PRRS. In PR-PRRS-ORF5, PR-PRRS-ORF3 + PR-PRRS-ORF5 and commercial PRRS vaccine vaccinated groups, 2 out of 6, 2 out of 6 and 2 out of 3 respectively showed antibody titer 2X against PRRS. However, the rest of piglets still showed no antibody activity. Among PR-PRRSORF5, PR-PRRS-ORF3 + PR-PRRS-ORF5 and commercial PRRS vaccine vaccinated groups showed significantly rise in antibody titers ranging from 2X to 8X at 2 weeks after challenge with PRRS-F1 virus. Pigs in the rest groups showed no rise in antibody titer at 2 weeks after challenge. In the aspect of PR antibody response, all pigs showed no antibody titer against PR at 2 weeks after vaccination. However, 2 out of 6 in each group of PR-PRRS-ORF3, PR-PRRS-ORF5 and PR-PRRS-ORF3 + PR-PRRS -ORF5 vaccinated pigs had antibody titer 2X against PR at 4 weeks after vaccination. For the commercial PR vaccine vaccinated pigs, 2 out of 3 had antibody titers 2X-4X against PR at 4 weeks after vaccination. Antibody titers against PR of all vaccinated pigs did not show any significant rise thereafter.application/pdf198250 bytesapplication/pdfzh-TW國立臺灣大學獸醫學系暨研究所[SDGs]SDG3reporthttp://ntur.lib.ntu.edu.tw/bitstream/246246/28696/1/892313B002200.pdf